A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
about
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsOverview of current immunotherapeutic strategies for gliomaCARs in chronic lymphocytic leukemia -- ready to driveA new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19Genetically modified T cells for the treatment of malignant diseaseAntibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsRecent advances in T-cell engineering for use in immunotherapyAre BiTEs the "missing link" in cancer therapy?Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaCase report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2Engineered T cells for cancer treatmentElimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.Strategies to genetically engineer T cells for cancer immunotherapy.Construction and evaluation of a novel humanized HER2-specific chimeric receptorThe future is now: chimeric antigen receptors as new targeted therapies for childhood cancerConsiderations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010CAR-modified T-cell therapy for cancer: an updated review.Driving CAR T-cells forwardRedirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.Bispecific antibodies engage T cells for antitumor immunotherapy.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceChimeric antigen receptors for T cell immunotherapy: current understanding and future directionsAdoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Genetic modification of T cellsGenetically engineered T cells for the treatment of cancer.A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.T cells redirected against CD70 for the immunotherapy of CD70-positive malignanciesAdoptive T cell therapy of cancer.Immunotherapy for malignant gliomaA high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomasGeneration of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells
P2860
Q26747695-B354D3C5-736C-4C91-8495-5AC2DFF1E577Q26753082-66E63239-1BDC-4C1E-85FC-B0DEC79BD2AEQ26776345-20CE65A3-B14A-4E6C-A87F-DC422F923657Q26830526-C4B100DA-78F6-4CC0-89E6-172FAC9F267CQ26849476-18A6A231-6348-4610-BDFF-968DE5F524F2Q26860657-34CA2038-76E0-42F5-989B-216D6799AAC1Q27011298-0D785ABE-126A-4CB8-9F6D-51EA1C11E8DAQ27027243-742E6CEA-F9DC-4B7D-9108-2D17452E4512Q27339832-EE94230C-AC3F-472E-AABE-5A45D0B8395DQ28080312-137FA308-796C-464C-9792-7269DF6F9FA8Q28083907-0E0B3DF0-6438-4766-A1DE-28D32B5511C5Q28537688-7C58CC7C-4820-40C4-A757-E99ADCE8DA66Q29620608-5F21BB91-618F-41AB-AF2E-E78A8A63329DQ33578792-D58ECB26-3773-48FE-BBCD-E90E5E70AD71Q33587034-1BDFF33A-02C8-44B5-BD0B-7C2E4B4CF5AEQ33603041-260696FE-D50F-42BB-A487-75A287452D89Q33655849-A6F9F6FE-4D13-42AA-8180-CE60C566B333Q33892746-8523BA69-2CA9-4EE1-895E-AF9C2C9D6F72Q33993529-B3D6E1B3-5318-49EC-91EE-37745F0E2D7AQ34025234-5E72B8E3-97EB-420D-8FBE-59D13F85DB28Q34044213-4F52339F-4354-4E52-BB26-C6C8EDA9D7E8Q34046505-D4C37F82-0CE2-470C-9A5B-A9F9210507C4Q34122292-BBEC0F96-A7D4-4B69-899A-84724FD840E7Q34139613-5471CE9D-5E30-4C9B-8B64-D9ED1E32CABBQ34174334-B3B2F030-9020-4CC7-AA7A-4F82C667C7DDQ34245416-9C0C94ED-27FE-4EF7-A82B-567379CE5834Q34248531-07A1C96D-35D3-49A3-B37F-A329711E844AQ34310912-F4CE3298-B03C-4146-AEFD-0754961A20AEQ34493886-F1E68C71-667F-448D-9071-45BD54B1A59FQ34557953-E0DB3D1D-55E8-4C3E-A9F7-856B62E3390BQ34621730-D3912100-13D1-491D-A911-4F1640D22435Q34644876-A6C22FE9-6275-41B6-8730-011F322AD3E3Q34645898-DBB952BA-6D7E-45A2-A51C-F96A8F516179Q34729692-F290EB63-7C82-49DD-9B8B-D842AE990B52Q34786615-4E56088A-1C83-4FF5-BAC4-3D2F43506E24Q34923799-573A89C6-B08A-44F0-8ADB-774CA98C3DC6Q34977470-2A6FDB9A-6B59-4C6C-849D-DBE0D7A5994CQ35114086-40944287-CE2D-4A3A-96D6-F24C4DBAE672Q35632469-6B77453C-9363-4A62-96BA-3F5AC57DFB52Q35651760-D0C1F872-F4A3-4BEC-A2BC-185ECA4B7CC1
P2860
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@en
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@nl
type
label
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@en
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@nl
prefLabel
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@en
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@nl
P2093
P356
P1476
A herceptin-based chimeric ant ...... ocytes and antitumor activity.
@en
P2093
James N Kochenderfer
Michel Sadelain
Qiong J Wang
Richard A Morgan
Shicheng Yang
Steven A Rosenberg
Xiaosong Zhong
Yangbing Zhao
Zelig Eshhar
Zhili Zheng
P304
P356
10.4049/JIMMUNOL.0900447
P407
P577
2009-11-01T00:00:00Z